Kelonia Therapeutics / Lilly
KLN-1010 is a BCMA-directed in vivo CAR-T candidate in Phase 1 for multiple myeloma, using the lentiviral iGPS platform. Lilly confirmed completion of the Kelonia acquisition in its Q2 2026 results. Early clinical findings remain investigational.
Corporate information
- Company entity
- Kelonia Therapeutics / Lilly
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- AcquiredNot verified
- Official corporate reference
- https://www.keloniatx.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
KLN-1010 is a BCMA-directed in vivo CAR-T candidate in Phase 1 for multiple myeloma, using the lentiviral iGPS platform. Lilly confirmed completion of the Kelonia acquisition in its Q2 2026 results. Early clinical findings remain investigational.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company Menu Close Expand mega menu Expand submenu Left icon for b
- Kelonia Therapeutics / Lilly — supporting primary disclosure